Multianalyte Test Predicts Drug Resistance in Esophageal Cancer
|
By LabMedica International staff writers Posted on 16 Mar 2015 |
|
Image: Histopathology of esophageal carcinoma showing infiltrating nests of neoplastic cells (Photo courtesy of Dr. Elliot Weisenberg, MD).
A multianalyte algorithmic immunohistochemistry (IHC) assay accurately identifies patients with locoregional esophageal adenocarcinoma (EC) who exhibit extreme resistance to neoadjuvant chemoradiotherapy.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
The test analyzes the localization of three protein biomarkers within a patient's tumor to classify the cancer as either responsive to or resistant to presurgical chemoradiotherapy and demonstrates strong accuracy and specificity in identifying patients with tumors that are unlikely to respond to standard presurgical (neoadjuvant) chemotherapy and radiation.
Scientists at Baylor College of Medicine (Houston TX, USA) and their colleagues studied archived biopsy specimens of EC which were subject to IHC examination of compartmentalized immunoreactivity of nuclear factor kappa B (NF-κB), Sonic Hedgehog (SHH), and GLI family zinc finger 1 (Gli-1), and a labeling index score was assigned to each biomarker. Pretreatment tumor biopsies were used to evaluate resistance (exCTRT) or responsiveness to (non-exCTRT) standard presurgical chemoradiotherapy (CTRT) regimens under accredited certified laboratory protocols.
According to validation studies, the DecisionDx-EC test (Castle Biosciences, Inc.; Friendswood, TX, USA) can reliably differentiate patients who are complete or partial responders to chemoradiotherapy from those who are non-responders. An initial, single center clinical validation study of 167 patients, which was used as training set for the current validation study, achieved an area under the curve (AUC) of 0.96 and an overall accuracy of 90%. The second validation, enrolled 64 patients from two independent institutions, and achieved an AUC of 0.96 and an overall accuracy of 84% for classifying which patients are likely to be highly resistant to presurgical chemotherapy treatment for esophageal cancer.
Derek Maetzold, BS, MBA, the President and CEO of Castle Biosciences, said, “Publication of these results is a culmination of our extensive program to analytically and clinically validate a new predictive test for esophageal cancer. DecisionDx-EC fits well within our strategy of developing and commercializing valuable prognostic tests that help physicians to select the most appropriate care for their patients.” The study was published on February 19, 2015, in the journal Gastrointestinal Cancer: Targets and Therapy.
Related Links:
Baylor College of Medicine
Castle Biosciences, Inc.
Gold Member
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Latest Pathology News
- Genetics and AI Improve Diagnosis of Aortic Stenosis
- AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
- Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
- Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
- Common Health Issues Can Influence New Blood Tests for Alzheimer’s Disease
- Blood Test Formula Identifies Chronic Liver Disease Patients with Higher Cancer Risk
- Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
- AI Tool Improves Breast Cancer Detection
- AI Tool Predicts Treatment Success in Rectal Cancer Patients
- Blood Test and Sputum Analysis Predict Acute COPD Exacerbation
- AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
- Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
Channels
Clinical Chemistry
view channel
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
Molecular Diagnostics
view channel
Blood Test Could Identify Biomarker Signature of Cerebral Malaria
Malaria remains a major cause of death and long-term disability in many low- and middle-income countries, with around 600,000 deaths reported globally each year. The most severe form, cerebral malaria,... Read more
World’s First Biomarker Blood Test to Assess MS Progression
Multiple sclerosis (MS) disease activity is caused by an abnormal immune response that results in damage to the brain and spinal cord. However, there is a lack of reliable tools to measure or predict MS progression.... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Technology
view channel
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
Glioblastoma is one of the most aggressive and fatal brain cancers, with most patients surviving less than two years after diagnosis. Treatment is particularly challenging because the tumor infiltrates... Read more
Industry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more
